A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer

Scandinavian Journal of Urology and Nephrology

Volumn 46, Issue 1, 2012, Pages 19-25

  Lyth, Johan ^a   Andersson, Swen Olof ^b   Andrén, Ove ^b   Johansson, Jan Erik ^b   Carlsson, Per ^c   Shahsavar, Nosrat ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cost effectiveness; Decision support; Prostate cancer; Radical prostatectomy; Randomized trial; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWEDEN; WATCHFUL WAITING;

EID: 84856187697     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2011.615759     Document Type: Article

References (26)

1. Kvale R, Auvinen A, Adami HO, Klint A, Hernes E, Moller B, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007;99:1881-7.
2. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002;60:458-63.
3. Klotz L, Zhang LY, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
4. Shortliffe EH. Medical informatics: computer applications in health care and biomedicine. 2nd ed. New York: Springer; 2001.
5. Griffin S, Claxton K, Hawkins N, Sculpher M. Probabilistic analysis and computationally expensive models: necessary and required? Value Health 2006;9:244-52.
6. Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess 2003;7(33):iii, ix-x, 1-157.
7. Calvert NW, Morgan AB, Catto JWF, Hamdy FC, Akehurst RL, Mouncey P, et al. Effectiveness and costeffectiveness of prognostic markers in prostate cancer. Br J Cancer 2003;88:31-5.
8. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 1997;12:299-305.
9. Scandinavian Prostatic Cancer Group. Expectant management or radical prostatectomy for early prostatic cancer (T0d-T2, NX, MO, G1-2): a multicentre study. SPCG-4. http://www.roc.se/prostata/spcg4.pdf.
10. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
11. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer.NEngl JMed 2005; 352:1977-84.
12. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst 2008;100: 1144-54.
13. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708-17.
14. Johansson E, Bill-Axelson A, Holmberg L, Onelov E, Johansson JE, Steineck G, et al. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting:the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol 2009;55: 422-32.
15. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson J, Norlen BJ, et al. Quality of life after radicalprostatectomy or watchful waiting. N Engl J Med 2002;347: 790-6.
16. Andersson SO, Andrén O, Lyth J, Stark J, Henriksson M, Adami HO, et al. Managing localized prostate cancer by radical prostatectomy or watchful waiting: cost analysis of a randomized trial (SPCG-4). Scand J Urol Nephrol 2011;45: 177-83.
17. FlemingC,WassonJH,AlbertsenPC,BarryMJ,Wennberg JE. A decision-analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2650-8.
18. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford:Blackwell Scientific Publications; 1994.
19. Kirkwood BR, Sterne JAC. Essential medical statistics. 2nd ed. Malden, MA: Blackwell Science; 2003.
20. Briggs A, Sculpher M, Dawson J, Fitzpatrick R, Murray D, Malchau H. Modelling the cost-effectiveness of primary hip replacement: how cost-effective is the Spectron compared to the Charnley prosthesis? Technical Report CHE Technical Paper Series 28. York: Centre for Health Economics; 2003.
21. Statistics Sweden, http://www.scb.se. Statistics Sweden. http://www.scb.se
22. Nelder JA, Wedderburn RWM. Generalized linear models. JRStatSoc A 1972;135:370-84.
23. Olsson U. Generalized linear models: an applied approach. Lund: Studentlitteratur; 2002.
24. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341-64.
25. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002;360:711-15.
26. The National Prostate Cancer Register (NPCR) in Sweden 2004-2008. http://www.vinkcancer.se/Global/Diagnoser/prostatacancer/rapporter/ prostataca-rapport-04-08. Pdf